BDX vs SYRE
Becton Dickinson vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
BDX
Becton Dickinson
50
Watch
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | BDX | SYRE |
|---|
| AI Score |
50
|
67
|
| Price |
$190.62
|
$106.63
|
| P/E Ratio |
57.45×
|
-54.69×
|
| ROE |
6.6%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
46.1%
|
0.0%
|
| Debt / Equity |
0.69×
|
0.00×
|
| Dividend Yield |
2.0%
|
0.0%
|
| RSI (14) |
77.5
|
57.5
|
| Beta |
0.258
|
3.026
|
| Expected Upside |
+1.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for BDX versus SYRE.
SYRE leads by 17 points.
SYRE scores 67/100 (Buy) versus BDX at 50/100 (Watch).
BDX Committee View
33% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — p/e of 53.2 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 53.2 is expensive by classic value standards — Value
- ROE of only 3.8% -- cheap may mean cheap for a reason — Value
- Revenue declining -2.6% YoY -- this is not a growth story right now — Growth
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical